Drug intelligence / Profile preview

GB-5001A

Development stage
Unknown
Lead developer
G2GBio
Modality
Nanoparticles → Drug Delivery Systems, Small Molecules
Administration
Subcutaneous, Intramuscular
01

Overview

GB-5001A is a long-acting injectable (LAI) formulation of donepezil, a reversible acetylcholinesterase inhibitor, developed by G2G Bio for the treatment of Alzheimer's disease. The drug utilizes G2G Bio's proprietary InnoLamp (Innovative Long-Acting MicroParticle) technology to create a sustained-release microsphere formulation. This delivery system is designed to maintain therapeutic plasma concentrations of donepezil for one month following a single administration, aiming to improve medication adherence and minimize the gastrointestinal side effects typically associated with the peak plasma levels of daily oral dosing. GB-5001A is part of a broader program (GB-5001) that has undergone early-stage clinical evaluation to demonstrate bioequivalence and safety compared to oral donepezil.

Other names
Donepezil 1-month sustained releaseDonepezil1-month sustained releaseDonepezil-1-month sustained releaseDonepezil LAI
02

Targets

Acetylcholinesterase

Beyond the preview

Go deeper on GB-5001A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on GB-5001A.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call